2024-01-08 NHLBI BioData Catalyst Ecosystem Release Notes
Introduction
The 2024-01-08 release marks the 16th release for the NHLBI BioData Catalyst® (BDC) ecosystem. This release includes several new features (e.g., enabling Azure and searching data without logging in) along with documentation and tutorials (e.g., data dictionary field documentation) to help new users get started on the system. Please find more detail on the new features and user support materials in the sections below.
The 2024-01-08 data releases include the addition of research on multisystem inflammatory syndrome in children linked to COVID-19, bone marrow transplant and pulmonary hypertension in sickle cell disease, atherosclerosis, and psoriasis. Please refer to the Data Releases section below for more information as well as the Data page on the BDC website.
Significant new features
Azure available on BDC Powered by Seven Bridges (BDC-SB): Velsera expanded their existing multi-cloud offerings by enabling Microsoft Azure (southcentralus) on BDC-SB. Users can select that computing and storage environment when creating a project. This allows users to avoid any egress charges when computing on data stored in Azure. This is of particular interest to users who want to connect their own Azure cloud buckets to BDC-SB.
SAS upgrade in BDC-SB: SAS on BDC-SB has been upgraded from SAS Viya 3.5 to SAS Studio 9.4. SAS 9.4 has improved functionality over SAS 3.5 including more complete data management solutions and additional programming languages.
Open PIC-SURE without login: Open PIC-SURE is now publicly available on BDC Powered by PIC-SURE (BDC-PIC-SURE), meaning no eRA Commons credentials are required to access the site. Researchers can access this site to search terms of interest, apply filters at the variable-value level, retrieve obfuscated, aggregate counts, and view single variable distributions of their selected cohort. This new functionality allows researchers to discover and interact with data available on BDC without needing to log in, decreasing the barrier to data exploration. Check out Open PIC-SURE here.
Data Hierarchies in BDC-PIC-SURE: Researchers are now able to view the data hierarchy associated with variables in BDC-PIC-SURE by clicking the “Data Tree” icon in the “Actions” column of the search results. This enables researchers to understand better how variables are related and obtain additional context for these variables. Note that this feature is currently in beta and will only be available for some studies. Feedback and input on this feature is welcome!
New user support materials and documentation
BDC-PIC-SURE Data Dictionary fields documentation: Documentation outlining the data dictionary fields returned from the PIC-SURE API was created. This provides a detailed account of what each field represents, including relationships between fields. This documentation can be found in the BDC-PIC-SURE GitBook here.
Data Releases
The table below highlights which studies were included in the 2024-01-08 data release. The release features research on long-term outcomes of multisystem inflammatory syndrome in children linked to COVID-19 (COVID19-MUSIC_GRU), bone marrow transplant for severe sickle cell disease (BioLINCC-BMT_CTN_HMB), and ApoA-1, atherosclerosis, and psoriasis (DIR-ApoA-1_Atherosclerosis_in_Psoriasis_GRU). Additionally, updated metadata is provided for the ongoing study on sildenafil therapy in treating pulmonary hypertension in sickle cell disease (walk-PHaSST). This data includes clinical files and is now available for access. The data is now available for access across the entire ecosystem.
| Study Name | phs I.D. # | Acronym | New to BioData Catalyst | New study version |
|---|---|---|---|---|
Long-TerM OUtcomes after the Multisystem Inflammatory Syndrome In Children (MUSIC) | phs002770.v1.p1.c1 | COVID19-MUSIC_GRU | Yes | Yes |
Unrelated Donor Reduced Intensity Bone Marrow Transplant for Children with Severe Sickle Cell Disease (BMT CTN-0601-BioLINCC) | phs003470.v1.p1.c1 | BioLINCC-BMT_CTN_HMB | Yes | Yes |
ApoA-1 and Atherosclerosis in Psoriasis (DIR) | phs003231.v1.p1.c1 | DIR-ApoA-1_Atherosclerosis_in_Psoriasis_GRU | Yes | Yes |
Treatment of Pulmonary Hypertension and Sickle Cell Disease With Sildenafil Therapy (walk-PHaSST) | phs002383.v1.p1.c1 | BioLINCC-Walk_PHaSST_DS-SCD-IRB-PUB-COL-NPU-MDS-RD | No | No |
Planned Upcoming Data Releases
| Study Name | phs I.D. # | Acronym | New to BioData Catalyst | New study version |
|---|---|---|---|---|
Genetic Epidemiology of COPD Study (COPDGene) | phs002910.v1.p1.c1 | COVID19-C4R_COPDGene_HMB | Yes | Yes |
Genetic Epidemiology of COPD Study (COPDGene) | phs002910.v1.p1.c2 | COVID19-C4R_COPDGene_DS-CS | Yes | Yes |
The Mediators of Atherosclerosis in South Asians Living in America (MASALA) | phs002980.v1.p1.c1 | COVID19-C4R_MASALA_HMB-IRB-COL | Yes | Yes |
Prevent Pulmonary Fibrosis (PrePF) | phs002975.v1.p1.c1 | COVID19-C4R_PrePF_HMB | Yes | Yes |
A Multi-site Observational Study of Post-Acute Sequelae of SARS-CoV-2 Infection in Adults (RECOVER) | phs003463.v1.p1.c1 | RECOVER-Adult | Yes | Yes |
Hispanic Community Health Study (HCHS) | phs003457.v1.p1.c1 | NSRR-HCHS | Yes | Yes |
Hispanic Community Health Study (HCHS) | phs003457.v1.p1.c2 | NSRR-HCHS | Yes | Yes |
NHLBI TOPMed: The Genetic Epidemiology of Asthma in Costa Rica (CRA) | phs000988.v5.p1.c1 | topmed-CRA_DS-ASTHMA-IRB-MDS-RD | No | Yes |
NHLBI TOPMed - NHGRI CCDG: Genes-Environments and Admixture in Latino Asthmatics (GALA II) | phs000920.v5.p2.c2 | topmed-GALAII_DS-LD-IRB-COL | No | Yes |
NHLBI TOPMed: HyperGEN - Genetics of Left Ventricular (LV) Hypertrophy | phs001293.v3.p1.c1 | topmed-HyperGEN_GRU-IRB | No | Yes |
NHLBI TOPMed: HyperGEN - Genetics of Left Ventricular (LV) Hypertrophy | phs001293.v3.p1.c2 | HyperGEN_DS-CVD-IRB-RD | No | Yes |
NHLBI TOPMed: Whole Genome Sequencing of Venous Thromboembolism (WGS of VTE) | phs001402.v3.p1.c1 | Mayo_VTE_GRU | No | Yes |
NHLBI TOPMed - NHGRI CCDG: Massachusetts General Hospital (MGH) Atrial Fibrillation Study | phs001062.v5.p2.c2 | MGH_AF_DS-AF-IRB-RD | No | Yes |
NHLBI TOPMed - NHGRI CCDG: Massachusetts General Hospital (MGH) Atrial Fibrillation Study | phs001062.v5.p2.c1 | MGH_AF_HMB-IRB | No | Yes |
NHLBI TOPMed: African American Sarcoidosis Genetics Resource | phs001207.v3.p1.c1 | Sarcoidosis_DS-SAR-IRB | No | Yes |
NHLBI TOPMed: Women's Health Initiative (WHI) | phs001237.v3.p1.c1 | WHI_HMB-IRB | No | Yes |
NHLBI TOPMed: Women's Health Initiative (WHI) | phs001237.v3.p1.c2 | WHI_HMB-IRB-NPU | No | Yes |
NHLBI TOPMed - NHGRI CCDG: Atherosclerosis Risk in Communities (ARIC) | phs001211.v4.p2.c2 | ARIC_DS-CVD-IRB | No | Yes |
NHLBI TOPMed - NHGRI CCDG: Atherosclerosis Risk in Communities (ARIC) | phs001211.v4.p2.c1 | ARIC_HMB-IRB | No | Yes |
NHLBI TOPMed: Genetics of Cardiometabolic Health in the Amish | phs000956.v5.p1.c2 | Amish_HMB-IRB-MDS | No | Yes |
NHLBI TOPMed: Australian Familial Atrial Fibrillation Study | phs001435.v2.p1.c1 | AustralianFamilialAF_HMB-NPU-MDS | No | Yes |
NHLBI TOPMed - NHGRI CCDG: Early-onset Atrial Fibrillation in the CATHeterization GENetics (CATHGEN) Cohort | phs001600.v3.p2.c1 | CATHGEN_DS-CVD-IRB | No | Yes |
NHLBI TOPMed: Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) | phs001472.v2.p1.c1 | ECLIPSE_DS-COPD-MDS-RD | No | Yes |
NHLBI TOPMed: Genetic Epidemiology Network of Arteriopathy (GENOA) | phs001345.v3.p1.c1 | GENOA_DS-ASC-RF-NPU | No | Yes |
NHLBI TOPMed: Genetic Epidemiology Network of Salt Sensitivity (GenSalt) | phs001217.v3.p1.c1 | GenSalt_DS-HCR-IRB | No | Yes |
NHLBI TOPMed: GOLDN Epigenetic Determinants of Lipid Response to Dietary Fat and Fenofibrate | phs001359.v3.p1.c1 | GOLDN_DS-CVD-IRB | No | Yes |
NHLBI TOPMed: Defining the time-dependent genetic and transcriptomic responses to cardiac injury among patients with arrhythmias | phs001434.v2.p1.c1 | miRhythm_GRU | No | Yes |
NHLBI TOPMed: Partners HealthCare Biobank | phs001024.v5.p1.c1 | PARTNERS_HMB | No | Yes |
NHLBI TOPMed: Pharmacogenomics of Hydroxyurea in Sickle Cell Disease (PharmHU) | phs001466.v2.p1.c3 | pharmHU_DS-SCD | No | Yes |
NHLBI TOPMed: Pharmacogenomics of Hydroxyurea in Sickle Cell Disease (PharmHU) | phs001466.v2.p1.c2 | pharmHU_DS-SCD-RD | No | Yes |
NHLBI TOPMed: Pharmacogenomics of Hydroxyurea in Sickle Cell Disease (PharmHU) | phs001466.v2.p1.c1 | pharmHU_HMB | No | Yes |
NHLBI TOPMed: REDS-III Brazil Sickle Cell Disease Cohort (REDS-BSCDC) | phs001468.v3.p1.c1 | REDS-III_Brazil_SCD_GRU-IRB-PUB-NPU | No | Yes |
NHLBI TOPMed: San Antonio Family Heart Study (SAFHS) | phs001215.v4.p2.c1 | SAFHS_DS-DHD-IRB-PUB-MDS-RD | No | Yes |
NHLBI TOPMed: Study of Asthma Phenotypes and Pharmacogenomic Interactions by Race-Ethnicity (SAPPHIRE) | phs001467.v2.p1.c1 | SAPPHIRE_asthma_DS-ASTHMA-IRB-COL | No | Yes |
NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women | phs001040.v5.p1.c1 | WGHS_HMB | No | Yes |
For detailed platform release notes please consult the following resources:
BDC-Gen3 release notes BDC-Terra release notes BDC-Seven Bridges release notes BDC-PIC-SURE release notes
Last updated